Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

about

Informatics for cancer immunotherapy.Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.

P2860

Q47290509-D13916CA-938B-4062-ADE1-269D86B4FB74 Q52592731-6AEF7846-06BC-4716-95A9-2F3470579C20 Q55513254-E126B70F-7910-4128-9BD3-BB050C2986B7

P2860

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q42329095

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

@en

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

@nl

type

Item

label

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

@en

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

@nl

prefLabel

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

@en

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

@nl

P1476

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

@en

P2093

William C Cho

http://www.w3.org/2001/XMLSchema#string

Xiaoming Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Imaging Biomarkers in Immunotherapy

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Combination cancer immunotherapies tailored to the tumour microenvironment.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.

Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.

P2888

s40169-017-0136-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40169-017-0136-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1054077897

http://www.w3.org/2001/XMLSchema#string

P698

28108884

http://www.w3.org/2001/XMLSchema#string

P932

5250626

http://www.w3.org/2001/XMLSchema#string

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

about

P2860

P2860

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932